... blocker (carvedilol) for 16 weeks, and, after a placebo washout period, were crossed over to the alternative regimen for another 16 weeks; 40 men were randomly assigned to receive placebo. Results indicated that carvedilol caused a decline in ...

... caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry. 1978 Apr;35(4):463–73. doi: 10.1001/archpsyc.1978.01770280073008. PMID: 365123. Population ... disorder: placebo-controlled double-blind pilot trial alone and combined ...

... 2- to 3-year follow-up characteristics of placebo-washout responders from the nortriptyline study of depressed 6- ...

... adequate?: NR Baseline/run-in period: 4 weeks placebo run-in Washout period(s): 2 weeks Duration of treatment: 26 ... 140-179 mm Hg after 2 weeks of washout with placebo Exclusion criteria: NR 1) Blood pressure: Change in ...

... trials have been of parallel group design and placebo controlled. A washout period at the end of the study was often included to remove the symptomatic effects of the active agent. In general, ... given placebo. 99 With this technique one group is randomised ...

... with moderate risk of bias compared melatonin or placebo for 3 months followed by a 1-month washout and 3 months of either melatonin or placebo. 68 Sleep latency and total sleep were significantly ...

... 69), or 40 mg/day (n = 61) or placebo (n = 60) for 4 weeks with forced dose escalation after a washout period. Eligible participants were aged 6 to 17 ... atomoxetine-slow titrating group, n = 61); or (3) placebo (n = 59) for nine ... screening and washout period. The primary outcome was the investigator-rated ...

... at 8 ml daily (400 mg CBDV) or placebo oil for 4 weeks, then crossed over after a 21-day washout. Using the numerical rating scale (NRS) pain scale (10-point scale), statistically significantly fewer patients achieved response ... reduction) with CBDV compared with placebo (38% vs. 81%, RR 0.46, 95% CI ...

... received 200 micrograms, 400 micrograms, 600 micrograms or placebo and had 3 or more wet nights during a 2 week washout at the end of the trial. The patients ...

... at 8 ml daily (400 mg CBDV) or placebo oil for 4 weeks, then crossed over after a 21-day washout. Using the NRS pain scale (10-point scale), statistically significantly fewer patients achieved response (≥30% pain reduction) with CBDV compared with placebo (38% vs. 81%, relative risk 0.46, 95% ...